Is venetoclax/venetoclax (Velcola) a chemotherapy drug or a targeted drug and analysis of the difference

Venetoclax (Venetoclax, also known as venetoclax) is an oral small molecule targeted drug and is not a traditional chemotherapy drug. Its main mechanism of action is to selectively inhibit BCL-2 protein, thereby inducing apoptosis in tumor cells. BCL-2 is an anti-apoptotic protein that many tumor cells rely on to avoid death. By binding to BCL-2, venetoclax blocks its inhibitory effect and promotes programmed death of cancer cells. This method of accurately attacking specific targets is a typical feature of targeted therapy and is essentially different from the broad-spectrum killing mechanism of traditional chemotherapy drugs.

Chemotherapy drugs usually have no clear target, but kill rapidly growing cells by destroying DNA synthesis and inhibiting cell division. This not only kills tumor cells, but also damages normal hematopoietic cells, gastrointestinal mucosa and hair follicle cells. Therefore, side effects such as bone marrow suppression, nausea and vomiting, and hair loss often occur. The targeted effect of venetoclax is relatively concentrated. Although it may also cause cytopenias, tumor lysis syndrome or increased risk of infection, the overall incidence and severity of side effects are relatively low, and it is well tolerated by patients.

Clinically, venetoclax is widely used in a variety of hematological malignancies, especially chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). It can be used as a single agent or in combination with other drugs, such as acalatinib or azacitidine, to form new treatment combinations. In some elderly patients who cannot tolerate intensive chemotherapy, venetoclax combined with low-intensity treatment regimens has shown good response rates and survival benefits, providing patients with a milder but effective treatment option.

Generally speaking, venetoclax is a targeted drug. Its difference lies not only in its precise mechanism of action, but also in its more controllable side effects and more flexible treatment methods. Compared with traditional chemotherapy, it marks an advancement in the concept of tumor treatment, shifting from simply "killing cancer cells" to "precisely blocking the pathogenic pathways." This new type of targeted therapy drug is gradually changing the treatment landscape of hematological tumors, and also brings more treatment opportunities and better quality of life to patients.

Reference link:https://www.drugs.com